Podcasts
Tune into the conversations that matter in prostate cancer, with our expert podcasts.
Guidelines can actually tell us what we should do when data are available, and the level of evidence is actually provided in guidelines, but often there is no evidence.
Podcast series: What's new in mCRPC?
Hosts Karim Fizazi and Stephen Freedland explore how evidence is reshaping mCRPC care – from guideline adoption and ARPI sequencing to advances in molecular profiling.
Podcast series: Expert exchanges – HRR in mPC
Alicia Morgans convenes global experts to discuss HRRm testing for mCRPC – spanning diagnostics, treatment sequencing, patient experience, and disparities in access.
News
PSA suppression predicts prognosis in mHSPC
Abiraterone-treated high-risk mHSPC patients with rapid, sustained PSA decline showed longer PSA PFS, rPFS, and overall survival.
mpMRI shows higher detection than PSMA PET/CT
A prospective study found mpMRI identified more local recurrence than PSMA PET/CT in men with biochemical failure post‑prostatectomy.
Black men face gaps in prostate cancer care
Qualitative evidence shows barriers to prostate cancer diagnosis in Black men, but tailored interventions can facilitate improved outcomes.
This content has been developed independently by Medthority who previously received educational funding from Pfizer in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
of interest
are looking at
saved
next event